ABI Pulls Plug on ‘Niche’ 1700 Array System As Users Cry Foul and Competitors Circle

ABI’s plan to exit the array business follows similar decisions by several companies over the last year, including Nanogen, and GE Healthcare. In ABI’s case, the company believes that its newly launched SOLiD sequencing system is a better platform for expression studies.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.